Scalper1 News
Small orphan-disease company Retrophin (RTRX) jumped to a new high near 26 Thursday after Leerink launched coverage of the stock with an outperform rating. Analyst Joseph Schwartz wrote that the company’s strategy depends on the pricing power of rare-disease drugs, which he says is sustainable. “Retrophin’s practice of acquiring under-appreciated therapies and raising the price many-fold has raised eyebrows; however, doing so puts the company at Scalper1 News
Scalper1 News